Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$gild $65.16 ^ 0.48 (0.74%)
Volume: 11,724,091 @01/29/21 7:57:47 PM EST
Wake up call on Brazil\S.America COVID Reinfection. Brazil Govt Is Working With PDSB On Second Vaccine ...
Good post, and very positive news for the markets
A national Covid strategy.
A good part of the orders Biden has signed so far relate to the coronavirus pandemic. The Current administration is building a muscular federal response to the crisis, a major change from Trump’s decentralized approach. The Biden plan will include a Pandemic Testing Board to establish unified standards across the country and boost supplies, which are still inadequate. There will be a Federal vaccination campaign, with federaly run mass vaccination centers and mobile units for rural areas. States and cities will get more funding and personnel for speedy vaccine deployment. The Biden administration will rebuild scientific agencies that Trump shackled or gutted. It will also establish procedures for reopening schools and provide more resources for local school districts.
It’s a mystery why the previous administration didn’t take these types of steps early in the pandemic. Public health experts and business leaders have stressed all along that massively scaled testing is crucial to safely operating businesses and reopening those forced to close. Vaccines will ultimately reduce the need for testing, but the vaccine rollout has been slow since it kicked off in December, with widespread immunity not likely until 2022 at the current pace.
Final Score Brilacidin 426, Remdesivir 130 .... a complete BLOW OUT!
Statistical Facts in Medical Science do matter!
BRILACIDIN SI *426*. Some keep babbling about safety.
Government RBLs recently declared BRILACIDIN has a SI of *426*.
Everyone was hoping to at least equal Gileads Remdesivir number of 129.87. A number good enough for FDA APPROVAL and 2 billion in revenues last year.
The higher the SI ratio the more EFFECTIVE and SAFE a drug would be during treatment for viral infections.
SAFE and EFFECTIVE are the key words.
The SI of a compound IS widely accepted parameter used to express a compounds efficacy in the INHIBITION of virus replication.
BRILACIDIN *426* efficiency has a 97% kill rate of the virus in lab testing. When combined with Remdesivir's 129 the kill rate did slightly jump up to 99.85%.
Simply put, peple would being saved at this very moment IF Gilead
was owner of BRILACIDIN *426*.
Seeing is believing. BRILACIDIN did so well that the RBLs STATED that BRILACIDIN should be lab tested against a host of other viruses.
You can believe what the major UNIVERSITIES, Government RBLs and highly honored scientists are saying after testing BRILACIDIN in the labs or you can belive the unsubstantiated claims of the other side. The agenda of the first group is to better society and bring help to the medical community. I can't say what the agenda is of the other side. God only knows..
BRILACIDIN *426* the SAFE ALTERNAIVE to many future ailments...
$GILD upgraded to $83.00
$gild $60.0 v -0.11 (-0.18%)
Volume: 13,251,119 @01/05/21 7:59:23 PM EST
Gilead Sciences or Biogen: Which Biotech Stock is a Better Pick for 2021?
https://ih.advfn.com/stock-market/NASDAQ/gilead-sciences-GILD/stock-news/84008440/gilead-sciences-or-biogen-which-biotech-stock-is
$GILD [value and yield, consider these five undervalued dividend stocks to buy:]
Gilead Sciences (NASDAQ:GILD)
https://finance.yahoo.com/news/5-undervalued-dividend-stocks-buy-194131394.html
https://www.griproom.com/fun/it-looks-like-gilead-is-about-to-merge-with-roche
Roche is one of the worst Pharma Companies to work for.
If True, watch Gilead lose the people that got them here.
This is like Frank Lorenzo buying up Eastern Airlines snd others.
Some chat, iRoche is the one killing the stock
NIH study uncovers blood vessel damage and inflammation in COVID-19 patients’ brains but no infection
Results from a study of 19 deceased patients suggests brain damage is a byproduct of a patient’s illness.
Scan of deceased COVID-19 patient’s brain
NIH researchers consistently found blood vessel damage in the brains of COVID-19 patients but no signs of SARS-CoV-2 infections. Arrows point to light and dark spots that are indicative of blood vessel damage observed in the study. NIAID
In an in-depth study of how COVID-19 affects a patient’s brain, National Institutes of Health researchers consistently spotted hallmarks of damage caused by thinning and leaky brain blood vessels in tissue samples from patients who died shortly after contracting the disease. In addition, they saw no signs of SARS-CoV-2 in the tissue samples, suggesting the damage was not caused by a direct viral attack on the brain. The results were published as a correspondence in the New England Journal of Medicine.
“We found that the brains of patients who contract infection from SARS-CoV-2 may be susceptible to microvascular blood vessel damage. Our results suggest that this may be caused by the body’s inflammatory response to the virus” said Avindra Nath, M.D., clinical director at the NIH’s National Institute of Neurological Disorders and Stroke (NINDS) and the senior author of the study. “We hope these results will help doctors understand the full spectrum of problems patients may suffer so that we can come up with better treatments.”
https://www.nih.gov/news-events/news-releases/nih-study-uncovers-blood-vessel-damage-inflammation-covid-19-patients-brains-no-infection
They better should work together and make a hell of a combination
IPIX phase II study for Brilacidin given the green light to start WITHOUT Remdesivir. Gilead needs to buy a boarding pass or miss this flight.
Pardon a newbie for busting in here. The street is all over Gilead. It forgets that the rheumatoid arthritis treatment was approved in Europe and Japan at the same time it was being held-up here. The street is also quite critical of the high-priced buyouts of these cancer research companies. I have followed this company for a long time and am interested in your feedback.
$gild $60.77 ^ 0.32 (0.53%)
Volume: 7,845,100 @12/11/20 7:59:47 PM EST
GILD acquires—(private)—MYR DmbH for $1.4B (€1.15B) plus contingencies:
https://www.businesswire.com/news/home/20201210005315/en/Gilead-Sciences-to-Acquire-MYR-GmbH
The acquisition will provide Gilead with Hepcludex (bulevirtide), which was conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020.
Gilead Announces Racial Equity Community Impact Fund to Support Black Communities Across United States
https://ih.advfn.com/stock-market/NASDAQ/gilead-sciences-GILD/stock-news/83864876/gilead-announces-racial-equity-community-impact-fu
Gilead Sciences Inc (GILD)
60.63 ? -0.93 (-1.51%)
Volume: 3,657,588 @12/07/20 1:20:32 PM EST
Bid Ask Day's Range
60.62 60.63 60.41 - 61.7
GILD Detailed Quote
A dividend would be welcome as we're trading around a two year low.
Love it here for the Long haul my friend..... fantastic article
New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes
https://www.researchgate.net/publication/341456311_New_GMP_manufacturing_processes_to_obtain_thermostable_HIV-1_gp41_virosomes_under_solid_forms_for_various_mucosal_vaccination_routes
https://www.mymetics.com/media-center/new-gmp-manufacturing-processes-obtain-thermostable-hiv-1-gp41-virosomes-under-solid-forms-various-mucosal-vaccination-routes/
I believe the time of this combination will come soon, maybe half of december
Brilacidin and Remdesivir shown to act synergistically in vitro, increasing overall inhibition against the novel coronavirus to 99.85 percent in a human lung cell line
Data suggest that Brilacidin and Remdesivir, with different but complementary primary mechanisms of action, may be an especially potent combination in treating COVID-19
https://www.globenewswire.com/news-release/2020/09/15/2093822/0/en/Laboratory-Testing-of-Brilacidin-for-COVID-19-in-Combination-with-Remdesivir-Reduces-Viral-Load-by-Nearly-100-Percent.html
Good luck and GOD bless,
Remdesivir, hailed — and taken — by Trump, doesn't work for coronavirus, World Health Organization declares
https://www.yahoo.com/news/remdesivir-hailed-and-taken-by-trump-doesnt-work-for-coronavirus-world-health-organization-declares-192616230.html
Good luck and GOD bless,
Looks like Gilead will lose some market share for Remdesivir. Perhaps this will finally prompt them to partner with Innovation Pharmaceuticals for Brilacidin.
https://www.cnbc.com/2020/11/19/coronavirus-who-tells-doctors-dont-use-gileads-remdesivir-splitting-with-fda.html?__source=androidappshare&fbclid=IwAR3z4fzJHQ1-U7LEK92Jfa-6ADdoY7GL8teKHO79HV9anxPyze-QCA5ghUU
BREAKING NEWS: $GILD Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
-- Results from First Phase 2 Trial Describing a Triple Combination Regimen Targeting NASH Presented at The Liver Meeting Digital Experience -- Gilead Sciences, Inc. (Nasdaq: GILD) and Novo Nordisk A/S (NASDAQ Copenhagen: NOVO B) today announced results from a Phase 2 pr...
Find out more GILD - Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
$gild $60.5 ^ 0.52 (0.87%)
Volume: 6,777,255 @11/13/20 7:59:41 PM EST
Brilacidin and FDA-approved remdesivir exhibit excellent synergistic activity in vitro against SARS-CoV-2.
https://science.gmu.edu/news/innovation-pharmaceuticals-and-george-mason-university-release-laboratory-testing-results
Good luck and GOD bless,
IPIX is not a drug. It is a company. Brilacidin is their main drug that was coupled with Remdesivir.
I agree. I am sure they are giving this to a lot of people behind the scenes!
-GILD
Even with a Vaccine we will still need a therapeutic Cure.
We might test some new lows over here..
-GILD
$gild $59.12 ^ 0.05 (0.08%)
Volume: 10,791,367 @11/09/20 5:52:39 PM EST
We are not dogs prone to chase squirrels. This doesn’t change the findings for Remdesivir + Brilacidin.
You're spamming garbage on a big board.
I’m sorry but I’m not familiar with the credential your buddy holds. “Drug Designer” sounds important... possibly...
The studies highlighting Brilacidin’s effectiveness are coming from the highest bio containment government labs.
Yeah except a study with 300 peeps is a joke. Had my buddy a drug designer look into it. Said it looks like fluff.
Additional formulation work is planned for the inhaled delivery of brilacidin for prophylactic use, toward controlling infection in the nasal passage and lungs by leveraging brilacidin’s ability to inhibit SARS-CoV-2 by disrupting viral integrity and impacting viral entry. Such development efforts, if successful, may enable brilacidin to emerge as a particularly effective and differentiated antiviral by preventing and/or decreasing early infectivity due to SARS-CoV-2.
Clearly, an effective COVID-19 therapeutic (or therapeutics in combination) ideally would control both viral load and the corresponding inflammatory damage due to SARS-CoV-2,93 and mitigate bacterial co-infections. Exhibiting three-in-one properties—antiviral, immuno/anti-inflammatory, and antibacterial—brilacidin is being developed for the intravenous treatment of COVID-19 in hospitalized patients and may be able to address different disease parameters within the one therapeutic treatment.
Remdesivir should be tested in combination with brilacidin ASAP
combination of brilacidin with remdesivir at 10µM and 2.5µM concentrations, respectively, reduced the viral infectious titer by >99%, thus providing a highly effective inhibition profile (Figure 5B) and achieving greater inhibition than with either compound alone. This synergistic inhibition continued to remain higher than 99% when the concentrations of both compounds were equal (2.5µM each) (Figure 5C).
$gild $59.0 v -0.63 (-1.06%)
Volume: 7,225,766 @11/06/20 7:59:50 PM EST
$GILD 11/03/20 Morgan Stanley Reinstates Equal-Weight $67.00
https://www.benzinga.com/stock/gild/ratings
This is what will bring the pandemic to an end. A real cure. This partnership better hurry or IPIX will steal the stage and the limelight. Brilacidin is clearly more effective than Remdesivir as a stand-alone drug and in vivo testing just around the corner.
Followers
|
165
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4867
|
Created
|
04/30/09
|
Type
|
Free
|
Moderators |
333 Lakeside Drive
Foster City, CA 94404
PER IHUB MGMT |
02-07-2021
DISCLAIMER: ONLY FOR MICK
https://investorshub.advfn.com/boards/profilea.aspx?user=1012
*The Board Monitor and herewithin , are not licensed brokers and assume NO responsibility for actions,
investments,decisions, or messages posted on this forum.
CONTENT ON THIS FORUM SHOULD NOT BE CONSIDERED ADVISORY NOR SOLICITATION
AUTHORS MAY HAVE BUYS OR SELLS WITH THE COMPANIES MENTIONED IN TRADING POSTERS SHOULD DUE DILIGENT BUYING OR SELLING.
ALL POSTING SHOULD BE CONSIDERED FOR INFORMATION ONLY. WE DO NOT RECOMMEND ANYONE BUY OR SELL ANY SECURITIES POSTED HEREWITHIN.
ANY trade entered into risks the possibility of losing the funds invested.
• There are no guarantees when buying or selling any security.Any
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |